 |
|
ЛІТЕРАТУРНІ ДЖЕРЕЛА
1. Алексеев Г. И., Бидерман Ф.М. Организационно-тактические и лечебные аспекты неотложной помощи при острых отравлениях//Неотложные состояния в клинике внутренних болезней/Докл. VI Всероссийского съезда терапевтов. — Горький. - 1990. - С. 257-258.
2. Амберт Э. Избирательная токсичность. Пер. с англ. — М,: Мир, 1971. —227 с.
3. Ананченко В.Г., Лушников Е.А., Мамонов А. В. и др. Гемосорбция и ультрафиолетовое облучение крови при отравлениях//Клинич. медицина. — 1988. — Т. 66, №2. - С. 122-126.
4. Афанасьев В. В. Отравления противоэпилептическими средствам /Клиническая токсикология детей и подростков/Под ред. И.В. Марковой и др. — СПб: Интермедика, 1998. — С. 229-235.
5. Бидерман Ф.М., Сосюкин А.Е. Концентрационные критерии рациональной инфузионной терапии тяжелых форм острых пероральных отравлений//Инфузионная терапия неотложных состояний. — Л.: Медицина, 1990. — С. 23—27.
6. Болдина И.Г., Миловский В.Г. Способ лекарственной профилактики повреждения эритроцитов при гемосорбции//Эндогенные интоксикации. — СПб: 1994. - С. 209-210.
7. Виллерт О.Х., Баботина И.К., Андреев A.M., Белокуров А.Ю. Инфузия 37 л жидкости в сутки при остром отравлении//Анестезиология и реаниматология - 1983. - №6. - С. 60-61.
8. Глозман О.С, Касаткина А.П. Детоксикационная терапия при острых отравлениях и аутоинтоксикациях. — Ташкент: Медицина, 1970. — 320 с.
9. Голиков С.Н., Саноцкий И.В., Тиунов Л.А. Общие механизмы токсического действия. — Л.: Медицина, 1986. — 280 с.
10. Горчаков В.Д., Сергиенко В. И., Владимиров В. Г. Селективные гемосорбенты. — М.: Медицина, 1989. — 223 с.
11. Гудивок И.И., Волошинский А.В., Харенко Т.Р., Палийчук Ю.Р. Клинические аспекты лимфогенной экстракорпоральной детоксикации при острых эндотоксикозах //Экстракорпоральная детоксикация и гемокоррекция в клинической практике/Тр. Воен.-мед. акад. — Т. 223, СПб: ВМедА, 1993. — С. 81-84.
12. Гуревич А.К. с соавт. Перитонеальный диализ в схемах и таблицах (пособие для врачей). СПб, 2003
13. Гуревич К.Я. с соавт. Перитонеальный диализ (пособие для врачей). Издание второе, переработанное и дополненное. СПб, 2003
14. Ливанов Г.А. Острые отравлениях//Энтеросорбция/Под ред. НА. Белякова. — Л.: Центр сорбционных технологий, 1991. — С. 258—265.
15. Ливанов Г.А., Батоцыренов Б.В., Калмансон М.Л. и др. Лечение эндотоксикоза при острых отравлениях нейротоксическими ядами как основа лечебной тактики //Тез. докл. 1-го съезда токсикологов России — М.: 1998. — С. 179.
16. Лопаткин Н.Д., Лопухин Ю.М. Эфферентные методы в медицине. — М.: Медицина, 1989. — С. 350.
17. Лопухин Ю.М., Молоденков М.Н. Гемосорбция. 2-е изд. — М.: Медицина, 1985. - С. 287.
18. Лужников Е.А., Гольдфарб Ю. С. Актуальные проблемы диагностики и лечения острых экзогенных отравлений//Терапевт, арх. — 1996. — Т. 68, №10. — С. 74-79.
19. Лужников Е.А., Гольдфарб Ю.С, Мусселиус С./".//Анестезиология и реаниматология. — 1993. — №1. — С. 55-66.
20. Лужников Е.А., Гольдфарб Ю.С, Поцхверия М.М. и др. Ультрафиолетовое облучение крови в интенсивной терапии острых отравлений//Анестезиология и реаниматология — 1989. — №4. — С. 31—35.
21. Лужников Е.А., Гольдфарб Ю.С, Широкова М.Н. и др. Реаниматологические аспекты сорбционной детоксикации в практике лечения острых экзогенных отравлений //Анестезиология и реаниматология. — 1987. — №5. — С. 35—37.
22. Лужников Е.А., Гольдфарб Ю.С. Коррекция нарушений химического гомеостаза при острых экзогенных отравлениях//Эфферентная терапия. — 1995. — Т. 1, №3. - С. 3-12.
23. Лужников Е.А., Гольдфарб Ю.С. Физиогемотерапия при острых экзо-и эндотоксикозах. — М.: 1991. — С. 5—14.
24. Лужников Е.А., Костомарова Л.Г. Острые отравления. — М.: Медицина, 1989. - С. 432.
25. Лужников Е.А., Фирсов Н.Н., Ярославский А.А. Опыт применения осмотического диуреза в клинической токсикологии//Терапевт. арх. — 1976. — Т. 48, №10. - С. 122-127.
26. Лужников Е.А., Ярославский А.А., Мусселиус С.Г., Барсуков АЭ.Р.//Применение перитонеального диализа при лечении тяжелых форм отравлений, осложненных экзотоксическим шоком //Анестезиология и реаниматология — 1977. — №1. — С. 82—85.
27. Лужников Е.А.,Дагаев В.Н., Горин Э. С. Критические состояния при острых отравлениях и их лечение//Терапевт. арх. — 1982. — Т.54, №9. — С. 3—8.
28. Максудов А. С, Багирова И.Р. Раннее применение плазмафереза в лечении острых отравлений ядом гюрзы//Тез. докл. 1-го съезда токсикологов России — М.: 1998. -С. 186.
29. Маркова И.В., Афанасьев В.В., Цыбулькин Э.К., Неженцев М.В. Клиническая токсикология детей о подростков. СПб.: Интермедика, 1998. — С. 302.
30. Нефрология. Учебное пособие для послевузовского образования. Под ред. Шилова Е.М. М, 2007.
31. Новиковская Т.В. Клиника и лечение острых отравлений дихлорэтаном: Автореф. дис... канд. мед. наук. — М., 1972. — С. 16.
32. Пилотович В.С., Калачик О.В. Хроническая болезнь почек. Методы заместительной почечной терапии. М, 2009.
33. Расулов АР., Бердымурадов Д.Б. Интенсивная терапия при укусах ядовитых змей //Анестезиология и реаниматология — 1994. — №3. — С. 59—60.
34. Семенюк Я.П. Применение форсированного диуреза при острых отравлениях //Воен.-мед. журн. — 1977. — №12. — С. 60-62.
35. Соколов А.А., Костюченко А.Л. 85 лет первому плазмаферезу в России/Эфферентная терапия. — 1998. — Т. 4, №2. — С. 51—67.
36. Сосюкин А.Е. Сорбционно-диализная терапия при острых пероральных отравлениях фосфорорганическими инсектицидами//Экстракорпоральная детоксикация и гемокоррекция в клинической практике/Тр. Воен.-мед. акад. — Т. 223. - СПб: ВМедА, 1993. - С. 37-42.
37. Сосюкин А.Е., Вельских А. Н., Зуев В.В. Соотношение экзо- и эндотоксикоза при острых отравлениях карбофосом//Актуальные вопросы военно-полевой терапии: Тез. докл. науч.-практ. конференции. — СПб, 1997. — С. 163.
38. Цыбулькин Э.К. Активная детоксикационная терапия//Клиническая токсикология детей и подростков/Под ред. И.В. Марковой и др. — СПб: Интермедика, 1998. - С. 105-110.
39. Челмакина В.П., Шель Ф.Г. Гемосорбция как основа детоксикационной терапии при острых отравлениях//Анестезиология и реаниматология. — 1987. — №4. - С. 72-74.
40. Челмакина В.П., Шель Ф.Г., Рябцева СВ. Мионевральный синдром и его лечение' у больных некоторыми острыми отравлениями//3дравоохр. Казахстана. - 1980. - №10. - С. 70-72.
41. Шиманко И.И., Савина А.С., Обуховский И.А. Об особенностях миоренального синдрома при острых отравлениях//Сов. медицина. — 1976. — №3. — С. 107-112.
42. Янчур Ф.М. Перитонеальный диализ: Автореф. дис... канд. мед. наук. — М., 1967. - С. 16.
43. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50: 81–114 (B)
44. Abraham S, Johnson CL, Najjar F: Weight and height of adults 18-74 years of age. DHEW Pub. No (PHS) 79-1659(211). Washington, DC, US Government Publications Office, Vital and Health Statistics, Series 11, 1979
45. Abramson D, Butler LD, Chrai S. Depyrogenation of a parenteral solution by ultrafiltration. J Parenter Sci Technol 1981; 35: 3–7 (B)
46. Abramson F, Gibson S, Barlee V, Bosch JP. Urea kinetic modeling at high urea clearances: implications for clinical practice. Adv Renal Replace Ther 1994; 1:5–14 (B)
47. Abreo K, Brown ST, Sella M. Correction of microcytosis following elimination of an occult source of aluminum contamination of dialysate. Am J Kidney Dis 1989; 13: 465–468 (B).
48. Abuelo JG, Chang BS. Is prostacyclin better than nothing for anticoagulation in haemodialysis? Lancet 1981; 2: 470– 471 (B)
49. Acchiardo SR, Hatten KW, Ruvinsky MJ et al. Inadequate dialysis increases gross mortality rate. ASAIO J 1992; 38: M282–M285 (B) SECTION II. Haemodialysis adequacy 27
50. Acchiardo SR, Moore LW, Burk L: Morbidity and mortality in hemodialysis patients. ASAIO Trans 36:M148-M151, 1990
51. Acchiardo SR, Moore LW, Latour PA: Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int Suppl 16:S199-S203, 1983
52. Adami S, Viapiana O, Gatti D et al. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 2008; 42: 267–270.
53. Agarwal R, Cronin RE. Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers. Am J Kidney Dis 1994; 23: 47–51 (A)
54. Agency for Toxic Substances and Disease Registry: Methanol toxicity . Am Fam Physician 1993; 47(1): 163-7.
55. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18–23.
56. Agresti J, Conroy JD, Olshan A et al. Heparin-free hemodialysis with Cuprophan hollow fiber dialyzers by a frequent saline flush, high blood flow technique. ASAIO Trans 1985; 31: 590–594 (B)
57. Ahmad S, Pagel M, Vizzo J, Scribner BH: Effect of the normalization of acid-base balance on postdialysis plasma bicarbonate. ASAIO Trans 26:318-322, 1980
58. Ahmed FE: Seafood safety . Committee on Evaluation of the Safety of Fishery Products 1991; Food & Nutrition Board, Institute of Medicine: National Academy Press.
59. Ahrenholz P, Winkler RE, Ramlow W, Tiess M, Mueller W.On-line haemodiafiltration with pre- and postdilution: acomparison of efficacy. Int J Artif Organs 1997; 20: 81–90 (B)
60. Akiba T, Tachibana K, Ozawa K et al. Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis. ASAIO J 1992; 38: M326–M330 (B)
61. Akizawa T, Kinugasa E, Koshikawa S. Endothelin and platelet activating factor. Possible indices for biocompatibility of hemodialysis. ASAIO Trans 1991; 37: M384–M385 (B)
62. Akkina SK, Connaire JJ, Snyder JJ, et al. Earlier is not necessarily better in preemptive kidney transplantation. Am J Transplant 2008;8:2071-6
63. Akmal M, Sawelson S, Karubian F, Gadallah M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 42:198-202, 1994
64. Akrum R, Frohlich M, Gerritsen AF, Daha MR, Chang PC. Ultrapure water for dialysate contributes to a lower activation state of peripheral blood mononuclear cells. Kidney Int 1999; 55: 1158–1171 (C)
65. Al Saady NM, Leatham EW, Gupta S et al. Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart 1999; 81: 134–140 (B)
66. Alexander S, Honda M. Continuous peritoneal diaysis for children: a decade of worldwide growth and development. Kidney Int 1993;43:S65-S74.
67. Alexander S. Pediatric uses of recombinant human erythropoietin: the outlook in 1991. Am J Kidney Dis 1991;18:42-53.
68. Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG. Impaired phagocytosis in dialysis patients: studies on mechanisms. Am J Nephrol 1991; 11: 102–111 (B)
69. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9–19 (B)
70. Allegra V, Vasile A, Maschio M, Mengozzi G. Immune response after vaccination with recombinant hepatitis surface antigen in maintenance hemodialysis patients and healthy controls. Nephron 1992; 61: 339–340 (B)
71. Allon M, Lockhart ME, Lilly RZ. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001; 60: 2013–2020
72. Allon M, Ornt DB, Schwab SJ et al. Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Hemodialysis (HEMO) Study Group. Kidney Int 2000; 58: 2178–2185
73. Almond, Clark: Nonsteroidal anti-inflammatory agents . Emergency Medicine A Comprehensive Guide 1995; 4th ed.: 792-795.
74. Amaral S, Hwang W, Fivush B, et al. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 2006;17:2878-2885.
75. Ambrosch A, Domroese U, Westphal S et al. Compositional and functional changes of low-density lipoprotein during hemodialysis in patients with ESRD. Kidney Int 1998; 54: 608–617 (B)
76. American Academy of Pediatrics: Naloxone dosage and route of administration for infants and children . Pediatrics 1990; 86(3): 484-485.
77. American Psychiatric Association: Diagnostic and statisical manual of mental disorders. 1994; 4th ed:.
78. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002;17:340-345.
79. Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95–96 (B)
80. Amitai Y, Yoram M, et al: Scorpion stings in children . Clinical Pediatrics 1885; 24: 136-40.
81. Amore A, Gyarnieri G, Atti M, Schena FP, Coppo R. Use of alkaline rinsing solution to prevent heypersensitivity reactions during hemodialysis: data from a multicentre retrospective analysis. J Nephrol 1999; 12: 383–389 (B)
82. Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR. A low molecular weight heparin (‘fragmin’) for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol 1989; 32: 290–296 (A)
83. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996; 124: 261–271 (B)
84. Anderson JE, Chang ASY, Anstadt MP. Polytetrafluoroethylene hemoaccess site infections. ASAIO J 2000; 46: S18–S21 (B)
85. Anderson R, Hart G, Crumpler C: Clonidine overdose: Report of six cases and review of the literature . Annals of Emergency Medicine 1981; 10(2): 107-112.
86. Anderstam B, Katzarski K, Bergstrom J Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997; 8: 1437–1442 (B)
87. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999; 10: 2177–2184 (B)
88. Andrassy K. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride. Blood Coagul Fibrinolysis 1993; 4 [Suppl 1]: S39–S43 (B)
89. Andress D. Intravenous versus oral vitamin D therapy in dialysis patients: what is the question? Am J Kidney Dis 2001;38:S41-S44.
90. Andrew EB, Swift BS, Swift TR: Ciguatera (Review) . J Toxicol Clin Toxicol 1993; 31(1): 1-29.
91. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am JMed 1980; 68: 59–65 (B)
92. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am JMed 1980; 68: 59–65 (B) 149. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am JMed 1980; 68: 59–65 (B)
93. Annibale B, Lahner E, Chistolini A, et al: Endoscopic evaluation of the upper gastrointestinal tract is worthwhile in premenopausal women with iron-deficiency anaemia irrespective of menstrual flow. Scand J Gastroenterol 38:239-245, 2003
94. Anochie I, Eke F. Acute renal failure in Nigerian children: Port Harcourt experience. Pediatr Nephrol 2005;20:1610-1614.
95. Anon: Self-treatment with herbal and other plant-derived remedies-rural Mississippi, 1993 . Morbidity and Mortality Weekly Report 1995; 44 (11): 204-7.
96. Ansell D, O’Neill JO, Johnson R, et al. Transplantation of older patients does not improve survival compared with those wait listed. Analysis of 9,700 wait listed patients in the UK. Transplantation 2008;86(2S):314
97. Anthon T, Jastremski M, Elliot W: Charcoal hemoperfusion for the treatment of a combined diltiazem and metoprolol overdose . Ann Emerg Med 1986; 15: 1344-1347.
98. Anthropometric data and prevalence of overweight for Hispanics:1982-84. Data from the National Health Survey, 1989. Hyattsville, MD, DHHS, US Government Publications Office, Vital and Health Statistics, Series 11, Nr 239, 1989
99. Antonen JA, Hannula PM, Pyhala R et al. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 2000; 86: 56–61 (B)
100. Apfelbaum JD, Caravati EM, Kerns WP: Cardiovascular Effects of Carbamazepine Toxicity . Ann Emer Med 1995; 25: 631-635.
101. Applebaum-Bowden D, Goldberg AP, Hazzard WR et al. Postheparin plasma triglyceride lipases in chronic hemodialysis: evidence for a role for hepatic lipase in lipoprotein metabolism. Metabolism 1979; 28: 917–924 (B)
102. Araki Y, Hataya H, Tanaka Y, et al. Long-term peritoneal dialysis is a risk factor of sclerosing encapsulating peritonitis for children. Perit Dial Int 2000;20:445-451.
103. Arduino MJ, Bland LA, McAllister SK, Favero MS. The effects of endotoxin-contaminated dialysate and polysulfone or cellulosic membranes on the release of TNF alpha during simulated dialysis. Artif Organs 1995; 19: 880–806 (B)
104. Arduino MJ. Proper mechanisms for assuring disinfectant concentrations for use in haemodialysis. Nephrol News Issues 1999; 13: 18, 23, 27 (B)
105. Arena J: Plants That Poison . Emergency Medicine June 15, 1989; pp. 20-64.
106. Arenas J, Sanchez-Paya J, Gonzales C et al. Audit on the degree of application of universal precautions in a haemodialysis unit. Nephrol Dial Transplant 1999; 14: 1001–1003 (B)
107. Argile´s A, Garcia-Garcia M, Derancourt J, Mourad G, Demaille JG. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits. Kidney Int 1995; 48: 1397–1405 (B)
108. Argiles A, Ficheux A, Thomas M et al. Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement. Kidney Int 1997; 52: 530–537 (B)
109. Arnadottir M, Berg AL, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients. Kidney Int 1997; 52: 1651–1655 (B)
110. Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14: 142–146 (B)
111. Arnadottir M, Berg AL, Kronenberg F et al. Corticotropininduced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: relation to apolipoprotein(a) size polymorphism. Metabolism 1999; 48:342–346 (B)
112. Arnadottir M, Brattstrom L, Simonsen O et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236– 240 (B)
113. Arnadottir M, Kurkus J, Nilsson-Ehle P. Different types of heparin in haemodialysis: long-term effects on post-heparin lipases. Scand J Clin Lab Invest 1994; 54: 515–521 (B)
114. Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 1995; 48: 779–784 (B)
115. Arnaout MA, Hakim RM, Todd RF, Dana N, Colten HR. Increased expression of an adhesion-promoting surface glycoproteinin the granulocytopenia of hemodialysis. N Engl J Med 1985; 312: 457–462 (B)
116. Arnesen E, Refsum H, Bonaa KH et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704–709 (B)
117. Arnow PM, Bland LA, Garcia-Houchins S, Fridkin S,Fellner SK. An outbreak of fatal fluoride intoxication in along-term haemodialysis unit. Ann Intern Med 1994; 121:339–344 (B)
118. Arnow PM, Garcia-Houchins S, Neagle MB et al. An outbreak of bloodstream infections arising from hemodialysis equipment. J Infect Dis 1998; 178: 783– 791 (B)
119. Arvanitidou M, Spaia S, Katsinas C et al. Microbiological quality of water and dialysate in all haemodialysis centres of Greece. Nephrol Dial Transplant 1998; 13: 949–954 (B)
120. Asaka M, Iida H, Izumino K, Sasayama S. Depressed natural killer cell activity in uraemia. Evidence for immunosuppressive factor in uraemic sera. Nephron 1988; 49: 291–295 (B)
121. Asayama K, Ito H, Nakahara C, et al. Lipid profiles and lipase activities in children and adolescents with chronic renal failure treated conservativelly or with hemodialysis or transplantation. Pediatr Res 1984;18:783-788.
122. Ascher E, Gade P, Hingorani A et al. Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg 2000 (Jan); 31 (1 pt 1): 84–92
123. Association. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 7–15
124. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). US Renal Data System: USRDS 2004 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004
125. Aterini S, Ippolito E, Salvadori M et al. Second messenger formation altered by different dialysis membranes in human leukocytes. Kidney Int 1994; 46: 461–466 (B)
126. Atger V, Duval F, Frommherz K, Drueke T, Lacour B. Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I. Atherosclerosis 1988; 74: 75–83 (B)
127. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
128. Atkins D, Briss PA, Eccles M et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005; 5: 25.
129. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia—relation to renal function and dialysis. Nephron 1991; 57: 401–410 (B)
130. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573–592 (C)
131. Attman PO, Samuelsson OG, Moberly J et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999; 55: 1536–1542 (B)
132. Attman PO. Hyperlipoproteinaemia in renal failure: pathogenesis and perspectives for intervention. Nephrol Dial Transplant 1993; 8: 294–295 (C)
133. Auerbach P: Marine envenomations . N Engl J Med 1991; 325: 486-493.
134. Auerbach P: Wilderness Medicine - Management of Wilderness and Environmental Emergencies . 1995; 780-81.
135. Auerbach PS: Marine envenomations. In Auerbach PS (Ed.) Wilderness Medicine: Management of Wilderness and Environmental Emergencies, 3rd ed . 1995; 1327-74.
136. Auerbach PS: Seafood toxidromes . Wilderness Medicine: Management of Wilderness and Environmental Emergencies 1995; 3rd ed: 1379-1384.
137. Auerbach PS: Wilderness medicine, management of wilderness and environmental emergencies . 1995;.
138. Aufderheide TP, White SM, et al: Inhalational and percutaneous methanol toxicity in two firefighters . Ann Emerg Med 1993; 22(12): 1916-8.
139. Auguet T, Senti M, Rubies PJ et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993; 8:1099–1103 (B)
140. Aull L, Chao H, Coy K. Heparin-induced hyperkalemia. DICP: Ann Pharmacotherap 1990; 24: 244–246 (B)
141. Auron A, Simon S, Andrews W, et al. Prevention of peritonitis in children receiving peritoneal dialysis. Pediatr Nephrol 2007;22:578-585.
142. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495–506 (C)
143. Austin MA, Mykkanen L, Kuusisto J et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995; 92: 1770–1778 (B)
144. Avram MM, Fein PA, Antignani A et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989; 87: 55N–60N (B)
145. Babb AL, Farrell PC, Uvelli DA, Scribner BH. Hemodialyzer evaluation by examination of solute molecular spectra. ASAIO Trans 1972; 18: 98–105, 122 (B)
146. Bacchini G, Cappello A, La Milia V, Andrulli S, Locatelli F. Color doppler ultrasonography imaging to guide transluminal angioplasty of venous stenosis. Kidney Int 2000; 58: 1810–1813
147. Bachmann J, Tepel M, Raidt H et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6: 121–125 (B)
148. Bacon NC. Heparin-induced disturbance of potassium homeostasis. Q JMed 1997; 90: 725 (B)
149. Bagnis R, Kuberski T, Laugier S: Clinical observations on 3009 cases of ciguatera (fish poisoning) in the South Pacific . Am J Trop Med Hyg 1979; 28: 1067-1073.
150. Bagnis R: Problems of toxicants in marine food products . Bull WHO 1970; 42: 69.
151. Bahlmann J, Schoter KH, Scigalla P, et al: Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study. Contrib Nephrol 88:90-106, 1991
152. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147–152 (C)
153. Baigent C, Wheeler DC. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant 2000; 15: 1118–1119 (C)
154. Bain RJI: Accidental digitalis poisoning due to drinking herbal tea . Br Med J 1985; 290: 1624.
155. Baker ME: Licorice and enzymes other than 11-beta-hydroxysteroid dehydrogenase: an evolutionary perspective . Steroids 1994; 59: 136-141.
156. Balfe J, Hanning R, Vigneux A. A comparison of peritoneal water and solute movement in younger and older children on CAPD. In: Fine R, Schaefer F, Mehls O, eds. CAPD in children. New York: Springer-Verlag New York, 1985:14-19.
157. Balfe J, Irwin M. Continuous ambulatory peritoneal dialysis in children. In: Legrain M, ed. Continuous ambulatory peritoneal dialysis. Amsterdam: Excerpta Medica, 1980:131-136.
158. Balfe J, Secker D, Coulter P, et al. Tube feeding in children on chronic peritoneal dialysis. Adv Perit Dial 1990;6:257-261.
159. Balfe J, Vigneux A, Willumsen J, et al. The use of CAPD in the treatment of children with end-stage renal disease. Perit Dial Bull 1981;1:35-38.
160. Balfe J. Intraperitoneal amino acids in children receiving chronic peritoneal dialysis. Perit Dial Int 1996;16:S515-S516.
161. Baluarte HJ, Grossman MS, Polinsky MD, et al. Experience with intermittent home peritoneal dialysis (IHPD) in children. Pediatr Res 1980;14:994.
162. Bambauer R, Meyer S, Jung H, Goehl H, Nystrand R. Sterile versus non-sterile dialysis fluid in chronic haemodialysis treatment. ASAIO Trans 1990; 36: M317–M320 (A)
163. Bambauer R, Rucker S, Weber U, Kohler M. Comparison of low molecular weight heparin and standard heparin in hemodialysis. ASAIO Trans 1990; 36: M646–M649 (B)
164. Bambauer R, Schauer M, Jung WK, Daum V, Vienken J. Contamination of dialysis water and dialysate. A survey of 30 centers. ASAIO J 1994; 40: 1012–1016 (B)119. Laurence RA, Lapierre ST. Quality of haemodialysis water: a 7-year multicenter study. Am J Kidney Dis 1995; 25:738–750 (B)
165. Bambauer R, Walther J, Jung WK. Ultrafiltration of dialysis fluid to obtain a sterile solution during haemodialysis. Blood Purif 1990; 8: 309–317 (C)
166. Bambauer R, Walther J, Meyer S et al. Bacteria- and endotoxin-free dialysis fluid for use in chronic haemodialysis.Artif Organs 1994; 18: 188–192 (C)
167. Bankhead MM, Toto RD, Star RA. Accuracy of urea removal estimated by kinetic models. Kidney Int 1995; 48: 785–793 (B)
168. Bansal R, Agarwal SK, Tiwari SC, Dash SC. A prospective randomized study to compare ultrasound-guided with nonultrasound-guided double lumen internal jugular catheter insertion as a temporary hemodialysis access. Ren Fail 2005; 27: 561–564
169. Barceloux DG, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of ethylene glycol poisoning. Ad Hoc Committee. J Toxi-col Clin Toxicol 1999;37:537-560.
170. Bardin T, Zingraff J, Shirahama T et al. Hemodialysisassociated amyloidosis and beta-2 microglobulin. Clinical and immunohistochemical study. Am J Med 1987; 83: 419–424 (B)
171. Bargman J, Nordfors L, Silverman E. The effect of in vivo erythropoietin on cytokine mRNA in CAPD patients. Adv Perit Dial 1994;10:129-134.
172. Barrera P, Janssen EM, Demacker PN, Wetzels JF, van der Meer JW. Removal of interleukin-1 beta and tumor necrosis factor from human plasma by in vitro dialysis with polyacrylonitrile membranes. Lymphokine Cytokine Res 1992; 11: 99–104 (B)
173. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein MB, Handa SP, Jindal KK, Kjellstrand CM, Levin A, Mandin H, Muirhead N, Richardson RM: Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 29:214-222, 1997
174. Basile C, Casino F, Lopez T. Percent reduction in blood urea concentration during dialysis estimates KtV in a simple and accurate way. Am J Kidney Dis 1990; 15: 40–45 (B)
175. Bass J: Effects of Enteral Tube Feeding on Absorption and Pharmacokinetic Profile of Carbamazepine . Epilepsia 1989; 30: 364-69.
176. Bastani B. McNeely M, Schmitz PG: Serum bicarbonate is an independent determinant of protein catabolic rate in chronic hemodialysis. Am J Nephrol 16:382-285, 1996
177. Bateman J, Chapman RD, Simpson D: Possible toxicity of herbal remedies . Scot Med J 1998; 43: 7-15.
178. Baud FJ, Barriot P, Toffis V: Elevated blood cyanide concentrations in victims of smoke inhalation . N Engl J Med 1991; 325: 1761-1766.
179. Baudouin-Legros M, Asdram L, Tondelier D, Paulais M, Anagnostopoulos T. Extracellular urea concentration modulates cAMP production in the mouse MTAL. Kidney Int 1996;50: 26–33 (B)
180. Baum M, Powell D, Calvin S, et al. Continuous ambulatory peritoneal dialysis in children: comparison with hemodialysis. N Engl J Med 1982;307:1537-1542.
181. Baumelou A, Singlas E, Petitclerc T et al. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron 1994; 68: 202–206 (B)
182. Baurmeister U, Travers M, Vienken J et al. Dialysate contamination and back filtration may limit the use of high-flux dialysis membranes. ASAIO Trans 1989; 35: 519–522 (C)
183. Baxter EH, Gallichio HA: Cross-neutralization by Tiger Snake (Notechis scutatus) Antivene and Sea Snake (Enhydrina schistosa) Antivene Against Several Sea Snake Venoms . Toxicon 1974; 12: 273-78.
184. Bay WH, Van Cleef S, Owens M. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. Am J Nephrol 1998; 18: 379–383
185. Baz M, Durand C, Ragon A et al. Using ultrapure water in haemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681–685 (B)
186. Beall CM, Goldstein MC: Hemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet. Am J Phys Anthropol 73:433-438, 1987
187. Beathard GA, Arnold P, Jackson J, Litchfield T. Aggressive treatment of early fistula failure. Kidney Int 2003; 64: 1487–1494
188. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic haemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475–486 (C)
189. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475–486 (C)
190. Beck-Sague CM, Jarvis WR, Bland LA et al. Outbreak of Gram-negative bacteremia and pyrogenic reactions in a hemodialysis center. Am J Nephrol 1990; 10: 397–403 (B)
191. Belay B, Esteban-Cruciani N, Walsh C, et al. The use of levo-carnitine in children with renal disease: a review and a call for future studies. Pediatr Nephrol 2006;21:308-317.
192. Belcon MC, Smith EK, Kahana LM, Shimizu AG. Tuberculosis in dialysis patients. Clin Nephrol 1982; 17: 14–18 (B)
193. Bellizzi V, Minutolo R, Terracciano V, et al: Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 40:549-555, 2002
194. Bello VA, Gitelman HJ. High fluoride exposure in haemodialysis patients. Am J Kidney Dis 1990; 15: 320–324 (C)Wathen RL, Burcham CW Jr. Understanding the dangers of fluoride during dialysis. Nephrol News Issues 1993; 7: 32–36 (C).
195. Ben-Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol 2000; 95: 3579–3383 (B)
196. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003–4008.
197. Benhamou E, Courouce AM, Jungers P et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143–147 (A)
198. Bennett WM, Aronoff GR, Morrison G et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983; 3: 155–193 (B)
199. Benowitz N: Beta-Adrenergic receptor blocker overdose . Haddad and Winchester, W.B. Saunders Co 1990; Second Edition: 1315-1326.
200. Bereket G, Fine R. Pediatric renal transplantation. Pediatr Clin North Am 1995;42:1603-1628.
201. Bergstrom J, Furst P. Uraemic toxins. In: Drukker W,Parsons FM, Maher J, eds. Replacement of Renal Function by Dialysis. Martinus Nijhoff, Dordrecht: 1983; 354–390 (C)
202. Bergstrom J, Heimburger O, Lindholm B: Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used? Perit Dial Int 18:467-473, 1998
203. Bergstrom J, Lindholm B, Lacson E Jr et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 2000; 13: 163–175 (C)
204. Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis [letter]. Lancet 1987; 1: 628–629 (C)
205. Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995; 6: 1329–1341 (C)
206. Berk W, Henderson W: Alcohols . Emergency Medicine: A Comprehensive Study Guide 1996; 765-72.
207. Berkahn L, Keating A: Hematopoiesis in the elderly. Hematology 9:159-163, 2004
208. Berkley SF: Dermatitis in grocery workers associated with high natural concentrations of furanocoumarins in celery . Ann Int Med 1986; 105: 351-355.
209. Berland Y, Brunet P, Ragon A, Frenkian G, Crevat A. Dialysate biocompatibility: evaluation and expectations. Contrib Nephrol 1993; 103: 76–88 (C)
210. Berland Y, Brunet P, Ragon A, Reynier JP. Dialysis fluid and water: their roles in biocompatibility. Nephrol Dial Transplant 1995; 10 [Suppl 10]: 45–47 (C)
211. Berman SJ, Hess JR, Sugihara JG, Wong ECC, Wong I, Siemens AW. Morbidity of infection in chronic hemodialysis. Dial Transplant 1979; 8: 324–328 (B)
212. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64:1514-1521, 2003
213. Berthoux F, Abramowicz D, Bradlet B, et al. European best practice guidelines for renal transplantation (Part 1). Nephrol Dial Transpl 2000;15:Suppl 7
214. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
215. Besarab A, Caro J, Jarrell B, et al: Effect of cyclosporine and delayed graft function on posttransplantation erythropoiesis. Transplantation 40:624-631, 1985
216. Besarab A, DeLucia T, Picarello N, Jungkind D. Formaldehyde, sodium hypochlorite, and metabisulphite are equally effective as sterilants for central delivery systems. ASAIO J 1993; 39: M590–M595 (B)
217. Besarab A, Levin A: Defining a renal anemia management period. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients.
218. Besarab A. Preventing vascular access dysfunction: which policy to follow. Blood Purif 2002; 20: 26–35
219. Bessen HA: Therapeutic and toxic effects of digitalis: William Withering, 1785. J Emerg Med 1986; 4: 243-282.
220. Besso L, Rovere A, Peano G et al. Prevalence of HCV antibodies in a uraemic population undergoing maintenance dialysis therapy and in the staff members of the dialysis unit. Nephron 1992; 61: 304–306 (B)
221. Besunder JB, Super DM, Anderson RL: Comparison of dimercaptosuccininc acid and calcium disodium ethylenediaminetetraacetic acid versus dimercaptopropanol and ethylenediaminetetraacetic acid in children with lead poisoning . J Pediatr 1997; 130: 966-71.
222. Beto JA, Bansal VK, Ing TS, Daugirdas JT. Variation in blood sample collection for determination of haemodialysis adequacy. Council on Renal Nutrition National Research Question Collaborative Study Group. Am J Kidney Dis 1998; 31: 135–141 (B)
223. Beto JA, Bansal VK: Interventions for other risk factors: Tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis 32:S112-S119, 1998 (suppl 3)
224. Bhat DJ, Tellis VA, Kohlberg WI, Driscoll B, Veith FJ. Management of sepsis involving expanded polytetrafluoroethylene grafts for hemodialysis access. Surgery 1980; 87: 445–450 (B)
225. Bhatia DS, Money SR, Ochsner JL et al. Comparison of surgical bypass and percutaneous balloon dilatation with primary stent placement in the dialysis patient: one-year follow-up. Ann Vasc Surg 1996; 10: 452–455
226. Biasioli S, Schiavon R, Petrosino L et al. Role of cellulosic and noncellulosic membranes in hyperhomocysteinemia and oxidative stress. ASAIO J 2000; 46: 625–634 (B)
227. Bick RL, Frenkel EP. Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy. Clin Appl Thromb Hemost 1999; 5 [Suppl 1]: S7–S15 (B)
228. Bielak LF, Klee GG, Sheedy PF et al. Association of fibrinogen with quantity of coronary artery calcification measured by electron beam computed tomography. Arterioscler Thromb Vasc Biol 2000; 20: 2167–2171 (B)
229. Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care 1996; 19: 625–628 (B)
230. Bigazzi R, Atti M, Baldari G. High-permeable membranes and hypersensitivity-like reactions: role of dialysis fluid contamination. Blood Purif 1990; 8: 190–198 (B)
231. Biglieri EG: Spectrum of mineralocorticoid hypertension . Hypertension 1991; 17(2): 251-261.
232. Bijsterveld NR, Hettiarachchi R, Peters R et al. Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 1999; 82 [Suppl 1]: 139–147 (B)
233. Bilo HJ, Homan van der Heide JJ, Gans RO, Donker AJ. Omega-3 polyunsaturated fatty acids in chronic renal insufficiency. Nephron 1991; 57: 385–393 (B)
234. Bingel M, Lonnemann G, Koch KM, Dinarello CA, Shaldon S.Plasma interleukin-1 activity during hemodialysis: the influence of dialysis membranes. Nephron 1988; 50: 273–276 (B)
235. Binzer M, Andersen P, Kullgren G: Clinical characteristics of patients with motor disability due to conversion disorder: A prospective control group study. Journal of Neurology, Neurosurgery, and Psychiatry 1997; 63: 83-88.
236. Birk HW, Kistner A, Wizemann V, Schu¨ tterle G. Protein adsorption by artificial membrane materials under filtration conditions. Artif Organs 1995; 19: 411–415 (B)
237. Birmbaumer D, Besson H: Alcohols and glycols . Emergency Medicine Concepts and Clinical Practice 1992; 3rd ed: 2520-32.
238. Bishai WR, Chaisson RE. Short-course chemoprophylaxis for tuberculosis. Clin Chest Med 1997; 18: 115–122 (B)
239. Biswal N, Mathai B, Bhataia BD: Scorpion sting envenomation: complications and management . Indian Pediatrics 1993; 30: 1055-9.
240. Blacher J, Demuth K, Guerin AP et al. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 1998; 18: 535–541 (B)
241. Blaikie A, Ellis J, Sanders R: Eye disease associated with handling pet tarantulas: three case reports . BMJ 1997; 314: 1524-25.
242. Blair SN, Applegate WB, Dunn AL, Ettinger WH, Haskell WL, King AC, Morgan TM, Shih JA, Simons-Morton DG: Activity Counseling Trial (ACT): Rationale, design, and methods. Activity Counseling Trial Research Group. Med Sci Sports Exercise 30:1097-1106, 1998
243. Blake J, Burkart J, Churchill D. Recommended clinical practices for maximizing peritoneal dialysis clearances. Perit Dial Int 1996;16:448-456.
244. Bland LA, Arnow PM, Arduino MJ, Bova J, McAllister SK. Potential hazards of deionization systems used for water purification in haemodialysis. Artif Organs 1996; 20: 2–7 (B)
245. Bland LA, Favero MS, Oxborrow GS, Aguero SM, Searcy BP, Danielson JW. Effect of chemical germicides on the integrity of hemodialyzer membranes. ASAIO Trans 1988; 34:172–175 (B)
246. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic haemodialysis patients. J Am Soc Nephrol 1995; 5: 1703–1708 (B)
247. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995; 5: 1703–1708 (B)
248. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995; 5: 1703–1708 (B)
249. Blaufox MD, Hampers CL, Merrill JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. ASAIO Trans 1966; 12: 207–209 (B)
250. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655–63.
251. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium3phosphate product with mortality risk in chronic hemodialysis patients:a national study. Am J Kidney Dis 1998; 31: 607–617 (B)
252. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226–1237 (C)
253. Bloembergen WE, Hakim RM, Stannard DC et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999; 33: 1–10 (B)
254. Bloembergen WE, Port FK. Epidemiological perspective on infections in chronic dialysis patients. Adv Ren Replace Ther 1996; 3: 201–207 (C)
255. Bloembergen WE, Stannard DC, Port FK et al. Relationship of dose of haemodialysis and cause-specific mortality. Kidney Int 1996; 50: 557–565 (B)
256. Bloembergen WE, Stannard DC, Port FK et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996; 50: 557–565 (B)
257. Blomquist S, Malmros C, Martensson L, Tho¨ rne J. Absence of lung reactions after complement depletion during dialysis: an experimental study in pigs. Artif Organs 1991; 15: 397–401 (B)
258. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis 1996; 27: 687–694 (B)
259. Blumenkrantz MJ, Gahl GM, Kopple JD, Kamdar AV, Jones MR, Kessel M, Coburn JW: Protein losses during peritoneal dialysis. Kidney Int 19:593-602, 1981
260. Blumenthal M: The Complete Medicinal Herb . DK Publishing 1993;.
261. Blythe DG, DeSylva DP, Fleming LE: Clinical experience with IV mannitol in the treatment of ciguatera . Bull Soc Pathol Exot 1992; 85: 425.
262. Boaz M, Matas Z, Biro A et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34: 438–444 (B)
263. Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078–1083 (B)
264. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213–1218 (A)
265. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000; 86: 19L–22L (B)
266. Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG. Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 1990; 5: 504–517 (B) SECTION VI. Haemodialysis-associated infection 83
267. Boelaert JR, Daneels RF, Schurgers ML et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130–134 (B)
268. Boelaert JR, De Baere YA, Geernaert MA, Godard CA, Van Landuyt HW. The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. J Hosp Infect 1991; 19 [Suppl B]: 41–46 (B)
269. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91: 1979–1986 (B)
270. Boelaert JR, De Smedt RA, De Baere YA et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 278–281 (A)
271. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18: 660–667 (B)
272. Boelaert JR, Van Landuyt HW, De Baere YA et al. Staphylococcus aureus infections in haemodialysis patients: pathophysiology and use of nasal mupirocin for prevention. J Chemother 1995; 7 [Suppl 3]: 49–53 (C)
273. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235–239 (B)
274. Boelaert JR, Van Landuyt HW, Valcke YJ et al. The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients. J Infect Dis 1987; 156: 384–387 (B)
275. Boelaert JR, van Roost GF, Vergauwe PL et al. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clin Nephrol 1988; 29: 261–266 (B)
276. Boelaert JR. Staphylococcus aureus infection in haemodialysis patients. Mupirocin as a topical strategy against nasal carriage: a review. J Chemother 1994; 6 [Suppl 2]: 19–24 (B)
277. Boen S, Mion C, Curtis F, et al. Periodic peritoneal dialysis using the repeated puncture technique and an automated cycling machine. Trans Am Soc Artif Intern Organs 1964;10:409-414.
278. Bogdan GM, Dart RC: Prolonged and recurrent coagulopathy after North American pit viper envenomation (abstract) . Ann Emerg Med 1996; 27: 820.
279. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107–114 (B)
280. Bommer C, Werle E, Walter-Sack I et al. D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. J Am Soc Nephrol 1998; 9: 90–96 (B)
281. Bommer J, Gemsa D, Waldherr R, Kessler J, Ritz E. Plastic filing from dialysis tubing induces prostanoid release from macrophages. Kidney Int 1984; 26: 331–337 (B)
282. Bommer J, Pernicka E, Kessler J, Ritz E. Reduction of silicone particle release during haemodialysis. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 287–290 (B)
283. Bommer J, Ritz E, Andrassy K et al. Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc Eur Dial Transplant Assoc 1983; 20: 161–168 (B)
284. Bommer J, Ritz E, Waldherr R. Silicone-induced splenomegaly. Treatment of pancytopenia by splenectomy in a patient on hemodialysis. N Engl J Med 1981; 305: 1077–1079 (B)
285. Bommer J, Vergetis W, Andrassy K et al. Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J 1995; 41: 127–131 (A)
286. Bommer J, Weinreich T, Lovett DH et al. Particles from dialysis tubing stimulate interleukin-1 secretion by macrophages. Nephrol Dial Transplant 1990; 5: 208–213 (B)
287. Bommer J, Wilhelms OH, Barth HP, Schindele H, Ritz E. Anaphylactoid reactions in dialysis patients: role of ethylene oxide. Lancet 1985; 2: 1382–1385 (B)
288. Bond GR, Burkhart KK: Thrombocytopenia following timber rattlesnake envenomation . Ann Emerg Med 1997; 30: 40-4.
289. Bond GR: Antivenin administration for Centruroides scorpion sting: risks and benefits . Annals of Emergency Medicine 1992; 21: 788-91.
290. Bonomini V, Coli L, Scolari MP, Stefoni S. Structure of dialysis membranes and long-term clinical outcome. Am J Nephrol 1995; 15: 455–462 (B)
291. Bonomini V, Coli L, Scolari MP, Stefoni S. Structures of dialysis membranes and long term clinical outcomes. Am J Nephol 1995; 15: 455–462 (B)
292. Boogaerts MA, Yamada O, Jacob HS, Moldow CF. Enhancement of granulocyte-endothelial cell adherence and granulocyte-induced cytotoxicity by platelet release products. Proc Natl Acad Sci USA 1982; 79: 7019–7023 (B)
293. Borah M, Schoenfeld P, Gotch F, et al. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 1978;14:491-500.
294. Borah M, Shoenfeld P, Gotch FA et al. Nitrogen balance during intermittent dialysis therapy for uraemia. Kidney Int 1978; 14: 491–500 (B)
295. Borah MF, Schoenfeld PY, Gotch FA et al. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 1978; 14: 491–500 (B)
296. Borah MF, Schoenfeld PY, Gotch FA, Sargent JA, Wolfsen M, Humphreys MH: Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14:491-500, 1978
297. Bories PC, Subbaiah PV, Bagdade JD. Lecithin: cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients. Nephron 1982; 32: 22–27 (B)
298. Borm JJ, Krediet R, Sturk A, ten Cate J. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis 1986; 16 [Suppl 2]: 59–68 (A)
299. Borovnicar DJ, Wong KC, Kerr PG, Stroud DB, Xiong DW, Strauss BJ, Atkins RC: Total body protein status assessed by different estimates of fat-free mass in adult peritoneal dialysis patients. Eur J Clin Nutr 50:607-616, 1996
300. Borron SW, Baud FJ: Acute cyanide poisoning: Clinical spectrum, diagnosis, and treatment . Arch Toxicol Indust Hygiene 1996; 47: 307-322.
301. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ: Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24:495-499, 2001
302. Bosse GM, Arnold TC: Overdose with sustained-release lithium preparations . J Emerg Med 1992; 10: 719-700.
303. Bosticardo GM, Avalle U, Giacchino F, Alloatti S. Comparison of a modified urea kinetic model direct dialysis quantification and classic urea kinetic modeling. ASAIO J 1995;41: M798–M800 (B)
304. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10–20 (C)
305. Bostom AG, Shemin D, Lapane KL et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147–152 (B)
306. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93–103 (B)
307. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125: 91–101 (B)
308. Bostom AG, Shemin D, Nadeau MR et al. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 1995; 113: 129–132 (B)
309. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554– 2558 (B)
310. Bostom AG, Shemin D, Yoburn D et al. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 1996; 120: 241–244 (B)
311. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and postdilution haemofiltration in four different membranes. Blood Purif 1998; 16: 261–268 (B)
312. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and post-dilution hemofiltration in four different membranes. Blood Purif 1998; 16: 261–268 (B)
313. Bourquelot P, Cussenot O, Cordy P, et al. Microsurgical creation and follow-up of arteriovenous fistulae for chronic haemodialysis in children. Pediatr Nephrol 1990;4:156-159.
314. Bourquelot P, Raynaud F, Pirozzi N. Microsurgery in children for creation of arteriovenous fistulas in renal and non-renal diseases. Ther Apher Dial 2003;7:498-503.
315. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. Aquantitative assessment of plasma omocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049–1057 (B)
316. Bousquet J, Maurice F, Rivory JP et al. Allergy in long-term hemodialysis. II. Allergic and atopic patterns of a population of patients undergoing long-term hemodialysis. J Allergy Clin Immunol 1988; 81: 605–610 (B)
317. Bouts A, et al. Standard peritoneal permeability analysis in children. J Am Soc Nephrol 2000;11:943-950.
318. Bown B: Encyclopedia of hebs and their uses . Dorling Kindersley 1995;.
319. Boyer D: The American Zoo and Aquarium Association and the American Association of Poison Control Centers Antivenin Index . 1994; 16-7.
320. Brady JP, Hasbargen JA: Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis 31:35-40, 1998
321. Braitberg G, et. al: Toxic Plant Ingestions . Wilderness Medicine 1995; pp. 862-889.
322. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520–2526 (B)
323. Braun DK, Janssen DA, Marcus JR, Kauffman CA. Cryptococcal infection of a prosthetic dialysis fistula. Am J Kidney Dis 1994; 24: 864–867 (B)
324. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394–401 (B)
325. Bray SH, Tung RL, Jones ER: The magnitude of metabolic acidosis is dependent on differences in bicarbonate assays. Am J Kidney Dis 28:700-703, 1996
326. Brem A, Lambert C, Hill C, et al. Clinical morbidity in pediatric dialysis patients: data from the Network 1 Clinical Indicator Project. Pediatr Nephrol 2001;16:854-857.
327. Brent J, Kulig K: Mushrooms . In, Haddad's Clinical Management of Poisoning and Drug Overdose, 3rd ed. 1998; 365-374.
328. Bressler R: The Unripe Akee-Forbidden Fruit. . NEJM 1976; 295: 500-501.
329. Brewer E. Growth of small children managed with chronic peritoneal dialysis and nasogastric tube feedings: 203 months experience in 14 patients. Adv Perit Dial 1990;6:269-272.
330. Brimacombe J: Use of calcium chloride for propranolol overdose. . Anaethesia 1992; 47: 907-908.
331. Brimble KS, Rabbat ChG, Treleaven DJ, Ingram AJ.Utility of ultrasonographic venous assessment prior to forearm arteriovenous fistula creation. Clin Nephrol 2002; 58: 122–127
332. Brittin GM, Brecher G, Johnson CA, Elashoff RM: Stability of blood in commonly used anticoagulants. Use of refrigerated blood for quality control of the Coulter Counter Model S. Am J Clin Pathol 52:690-694, 1969
333. Brod J, Hornych A: Effect of correction of anemia on the glomerular filtration rate in chronic renal failure. Isr J Med Sci 3:53-59, 1967
334. Brooks PM, Day RO: Nonsteroidal Antiinflammaroty drugs: Differences and similarities . N Engl J Med 1991; 324: 1716-1725.
335. Brouhard B, Berger M, Cunningham R, et al. Home peritoneal dialysis in children. Trans Am Soc Artif Intern Organs 1979;25:90-94.
336. Brouillard M, Reade R, Boulanger E et al. Erythrocyte sedimentation rate, an underestimated tool in chronic renal failure. Nephrol Dial Transplant 1996; 11: 2244–2247 (B)
337. Brown C, Shepherd S: Marine trauma, evenomations and intoxications . Emerg Med Clin North Am 1992; 10: 385-408.
338. Brown CH, Leverett LB, Lewis CW, Alfrey CP, Hellums JD. Morphological, biochemical, and functional changes in human platelets subjected to shear stress. J Lab Clin Med 1975; 86: 462–471 (B)
339. Brownbridge G, Fielding D. Psychosocial adjustment and adherence to dialysis treatment regimes. Pediatr Nephrol 1994;8:744-749.
340. Brownbridge G, Fielding D. Psychosocial adjustment to end-stage renal failure: comparing haemodialysis, continuous ambulatory peritoneal dialysis and transplantation. Pediatr Nephrol 1991;5:612-662.
341. Browning RG, et al.: Cinical toxicity of ethylene glycol monoalkyl ethers . Hum Exp Toxicol 1994; 13(5): 325-335.
342. Broyer M, Le Bihan C, Charbit M, et al. Long-term social outcome of children after kidney transplantation. Transplantation 2004;77:1033-1037.
343. Bruguera M, Rodicio JL, Alcazar JM et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8 [Suppl]: S47–S49 (B)
344. Brunet P, Berland Y. Water quality and complications of haemodialysis. Nephrol Dial Transplant 2000; 15: 578–580 (C)
345. Brunett J, Calton G: Jellyfish evenomations syndromes updated . Ann Emerg Med 1987; 16: 1000-1005.
346. Brunzell JD, Albers JJ, Haas LB et al. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977; 26: 903–910 (B)
347. Bryson P: Nonsteroidal Antiinflammatory Agents . Comprehensive Review in Toxicology 2nd ed: 445-454.
348. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432–438 (B)
349. Bucher HC, Guyatt GH, Cook DJ et al. Users’ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771–778.
350. Buckley NA, Whyte IM, Dawson AH: Pheniramine: A much abused drug . Med J Aust 1994; 160: 188-92.
351. Bunchman T, Donckerwolcke R. Continuous arterial-venous diahemofiltration and continuous veno-venous diahemofiltration in infants and children. Pediatr Nephrol 1994;8:96-102.
352. Bunchman T, McBryde K, Mottes T, et al. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 2001;16: 1067-1071.
353. Buoncristiani U, Quintaliani G, Cozzari M, Giombini L, Ragaiolo M. Daily dialysis: long-term clinical metabolic results. Kidney Int Suppl 1988; 24: S137–S140 (B)
354. Buoncristiani U. Fifteen years of clinical experience with daily haemodialysis. Nephrol Dial Transplant 1998; 13 [Suppl 6]: 148–151 (B)
355. Burch JM, Agarwal R, et al: The treatment of crotalid envenomation without antivenin . J Trauma 1988; 28: 35-43.
356. Burgelman M, Vanholder R, Fostier H, Ringoir S. Estimation of parameters in a two-pool urea kinetic model for haemodialysis. Med Engl Phys 1997; 19: 69–76 (B)
357. Burgess E: Prolonged hemodialysis in methanol intoxication . Pharmacotherapy 1992; 12(3): 238-9.
358. Burgess JL, Dart RC: Snake venom coagulopathy: Use and abuse of blood products in the treatment of pit viper envenomation . Ann Emerg Med 1991; 20: 795-801.
359. Burkart J, Schreiber M, Korbet S, et al. Solute clearance approach to adequacy of peritoneal dialysis. Perit Dial Int 1996;16:457-470.
360. Burke SK, Dillon MA, Hemken DE et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003; 10: 133–145.
361. Burkhardt KK, Kulig KW: The other alcohols: Methanol, ethylene glycol, and isopropanol . Emerg Med Clinics of North Am 1990; 8(4): 913-28.
362. Burkhart K: Methanol and ethylene glycol toxicity. J Toxicol Clin Toxicol 1997; 35(2): 149-150.
363. Burks JS, Walker JE, Rumack BH: Tricyclic antidepressant poisoning. Reversal of coma, choreoathetosis, and myoclonus by physostigmine . JAMA 1974; 230: 1405-7.
364. Busch EH, Ventura HO, Lavie CJ. Heparin-induced hyperkalemia. South Med J 1987; 8